Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TAPBP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TAPBP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TAPBP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TAPBP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/TAPBP_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TAPBP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TAPBP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TAPBP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TAPBP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TAPBP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004800210 | Cervix | CC | antigen processing and presentation of peptide antigen | 24/2311 | 62/18723 | 1.21e-07 | 6.07e-06 | 24 |
GO:00023968 | Cervix | CC | MHC protein complex assembly | 12/2311 | 19/18723 | 2.65e-07 | 1.12e-05 | 12 |
GO:001988210 | Cervix | CC | antigen processing and presentation | 32/2311 | 106/18723 | 8.61e-07 | 3.08e-05 | 32 |
GO:000248310 | Cervix | CC | antigen processing and presentation of endogenous peptide antigen | 11/2311 | 19/18723 | 2.89e-06 | 8.23e-05 | 11 |
GO:001988310 | Cervix | CC | antigen processing and presentation of endogenous antigen | 13/2311 | 26/18723 | 3.25e-06 | 8.80e-05 | 13 |
GO:001988510 | Cervix | CC | antigen processing and presentation of endogenous peptide antigen via MHC class I | 9/2311 | 17/18723 | 6.27e-05 | 8.94e-04 | 9 |
GO:00481938 | Cervix | CC | Golgi vesicle transport | 58/2311 | 296/18723 | 2.24e-04 | 2.54e-03 | 58 |
GO:000247410 | Cervix | CC | antigen processing and presentation of peptide antigen via MHC class I | 11/2311 | 28/18723 | 2.84e-04 | 3.07e-03 | 11 |
GO:00068907 | Cervix | CC | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 15/2311 | 52/18723 | 1.15e-03 | 9.39e-03 | 15 |
GO:00158337 | Cervix | CC | peptide transport | 46/2311 | 264/18723 | 9.69e-03 | 4.78e-02 | 46 |
GO:001988223 | Cervix | N_HPV | antigen processing and presentation | 17/534 | 106/18723 | 7.93e-09 | 1.60e-06 | 17 |
GO:000239622 | Cervix | N_HPV | MHC protein complex assembly | 8/534 | 19/18723 | 2.38e-08 | 3.18e-06 | 8 |
GO:004800223 | Cervix | N_HPV | antigen processing and presentation of peptide antigen | 12/534 | 62/18723 | 1.51e-07 | 1.30e-05 | 12 |
GO:001988314 | Cervix | N_HPV | antigen processing and presentation of endogenous antigen | 7/534 | 26/18723 | 6.06e-06 | 2.17e-04 | 7 |
GO:000248315 | Cervix | N_HPV | antigen processing and presentation of endogenous peptide antigen | 6/534 | 19/18723 | 1.03e-05 | 3.53e-04 | 6 |
GO:001988514 | Cervix | N_HPV | antigen processing and presentation of endogenous peptide antigen via MHC class I | 4/534 | 17/18723 | 1.16e-03 | 1.31e-02 | 4 |
GO:000247413 | Cervix | N_HPV | antigen processing and presentation of peptide antigen via MHC class I | 4/534 | 28/18723 | 7.78e-03 | 4.97e-02 | 4 |
GO:0048193 | Colorectum | AD | Golgi vesicle transport | 109/3918 | 296/18723 | 1.80e-10 | 1.68e-08 | 109 |
GO:0006890 | Colorectum | AD | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 27/3918 | 52/18723 | 7.67e-07 | 2.70e-05 | 27 |
GO:0015833 | Colorectum | AD | peptide transport | 77/3918 | 264/18723 | 8.90e-04 | 8.60e-03 | 77 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517053 | Oral cavity | EOLP | Human immunodeficiency virus 1 infection | 63/1218 | 212/8465 | 4.85e-09 | 8.71e-08 | 5.14e-08 | 63 |
hsa0461254 | Oral cavity | EOLP | Antigen processing and presentation | 29/1218 | 78/8465 | 4.69e-07 | 4.78e-06 | 2.82e-06 | 29 |
hsa0516361 | Oral cavity | NEOLP | Human cytomegalovirus infection | 55/1112 | 225/8465 | 2.32e-06 | 2.30e-05 | 1.45e-05 | 55 |
hsa0517061 | Oral cavity | NEOLP | Human immunodeficiency virus 1 infection | 49/1112 | 212/8465 | 4.05e-05 | 3.22e-04 | 2.02e-04 | 49 |
hsa0516371 | Oral cavity | NEOLP | Human cytomegalovirus infection | 55/1112 | 225/8465 | 2.32e-06 | 2.30e-05 | 1.45e-05 | 55 |
hsa0517071 | Oral cavity | NEOLP | Human immunodeficiency virus 1 infection | 49/1112 | 212/8465 | 4.05e-05 | 3.22e-04 | 2.02e-04 | 49 |
hsa0516926 | Prostate | BPH | Epstein-Barr virus infection | 70/1718 | 202/8465 | 1.06e-06 | 9.74e-06 | 6.03e-06 | 70 |
hsa0516326 | Prostate | BPH | Human cytomegalovirus infection | 74/1718 | 225/8465 | 4.87e-06 | 3.92e-05 | 2.43e-05 | 74 |
hsa0461227 | Prostate | BPH | Antigen processing and presentation | 28/1718 | 78/8465 | 9.64e-04 | 4.47e-03 | 2.76e-03 | 28 |
hsa0517020 | Prostate | BPH | Human immunodeficiency virus 1 infection | 60/1718 | 212/8465 | 2.96e-03 | 1.12e-02 | 6.92e-03 | 60 |
hsa05169112 | Prostate | BPH | Epstein-Barr virus infection | 70/1718 | 202/8465 | 1.06e-06 | 9.74e-06 | 6.03e-06 | 70 |
hsa05163111 | Prostate | BPH | Human cytomegalovirus infection | 74/1718 | 225/8465 | 4.87e-06 | 3.92e-05 | 2.43e-05 | 74 |
hsa04612112 | Prostate | BPH | Antigen processing and presentation | 28/1718 | 78/8465 | 9.64e-04 | 4.47e-03 | 2.76e-03 | 28 |
hsa05170110 | Prostate | BPH | Human immunodeficiency virus 1 infection | 60/1718 | 212/8465 | 2.96e-03 | 1.12e-02 | 6.92e-03 | 60 |
hsa0516927 | Prostate | Tumor | Epstein-Barr virus infection | 72/1791 | 202/8465 | 1.15e-06 | 1.09e-05 | 6.73e-06 | 72 |
hsa0516327 | Prostate | Tumor | Human cytomegalovirus infection | 74/1791 | 225/8465 | 2.27e-05 | 1.79e-04 | 1.11e-04 | 74 |
hsa0461228 | Prostate | Tumor | Antigen processing and presentation | 28/1791 | 78/8465 | 1.88e-03 | 7.76e-03 | 4.81e-03 | 28 |
hsa0517026 | Prostate | Tumor | Human immunodeficiency virus 1 infection | 62/1791 | 212/8465 | 3.05e-03 | 1.12e-02 | 6.94e-03 | 62 |
hsa0516935 | Prostate | Tumor | Epstein-Barr virus infection | 72/1791 | 202/8465 | 1.15e-06 | 1.09e-05 | 6.73e-06 | 72 |
hsa0516336 | Prostate | Tumor | Human cytomegalovirus infection | 74/1791 | 225/8465 | 2.27e-05 | 1.79e-04 | 1.11e-04 | 74 |